^
    Back
    Association details:
    Biomarker:CMTR1-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Cancer Biol Ther
    Title:

    CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

    Excerpt:
    NGS result revealed that this tumor specimen harbored a previously unknown CMTR1-ALK fusion variant...treatment was initiated with 250 mg crizotinib per day starting in September 2016. The disease still developed 1 month after drug treatment showing that this patient has no response to crizotinib.
    DOI:
    10.1080/15384047.2018.1480282